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Abstract
Is it feasible to create an analysis paradigm that can analyze and then accurately and quickly predict
known drugs from experimental data? PharML.Bind is a machine learning toolkit which is able to accomplish
this feat. Utilizing deep neural networks and big data, PharML.Bind correlates experimentally-derived drug
affinities and protein-ligand X-ray structures to create novel predictions. The utility of PharML.Bind is in
its application as a rapid, accurate, and robust prediction platform for discovery and personalized medicine.
This paper demonstrates that graph neural networks (GNNs) can be trained to screen hundreds of thousands
of compounds against thousands of targets in minutes, a vastly shorter time than previous approaches. This
manuscript presents results from training and testing using the entirety of BindingDB after cleaning; this
includes a test set with 19,708 X-ray structures and 247,633 drugs, leading to 2,708,151 unique protein-ligand
pairings. PharML.Bind achieves a prodigious 98.3% accuracy on this test set in under 25 minutes. PharML.Bind
is premised on the following key principles: 1) speed and a high enrichment factor per unit compute time,
provided by high-quality training data combined with a novel GNN architecture and use of high-performance
computing resources, 2) the ability to generalize to proteins and drugs outside of the training set, including
those with unknown active sites, through the use of an active-site-agnostic GNN mapping, and 3) the ability to
be easily integrated as a component of increasingly-complex prediction and analysis pipelines. PharML.Bind
represents a timely and practical approach to leverage the power of machine learning to efficiently analyze and
predict drug action on any practical scale and will provide utility in a variety of discovery and medical applications.
Keywords: protein-ligand interaction, drug discovery, docking, neural networks, machine learning, deep learn-
ing, artificial intelligence, affinity, X-ray, high-performance computing.
1 Introduction
ParmML.Bind is a novel, high-throughput, in sil-
ico framework for the acceleration of critical por-
tions of contemporary and future pharmaceutical drug-
discovery workflows. Specifically, PharML.Bind accel-
erates prediction of the binding of candidate drugs to
target proteins through utilization of experimentally-
derived 3D protein structures and associated drug
affinities. This is achieved by applying state-of-the-art
machine learning (ML) techniques to efficiently model
the rules governing affinity in a data-driven manner. Ef-
ficient and accurate drug discovery for target proteins,
as well as discovery of relevant proteins for candidate
drugs, is of primary interest to pharmaceutical compa-
nies, healthcare practitioners, and patients.
The area of computer-aided drug discovery (CADD)
was born as computational performance advanced to
the point that simulation of drug-target interactions
was possible with reasonable speed and accuracy.
CADD was founded on the capabilities of computers
to simulate drug-target interactions and proved to be
an efficient and rational drug discovery tool. However,
in the last decade, the prominence of artificial intelli-
gence (AI) and machine learning (ML) has been at the
forefront of the latest and most-advanced drug discov-
ery techniques. Using AI as a prediction tool is reaching
peak hype, and for good reason, as there is enormous
investment, excitement, and potential [29] [28].
Most software programs for drug docking predictions
used to date depend upon approximations to estimate
binding energy between the drug and target. Among
such programs are the popular Dock [9], AutodockV-
ina [11], GLIDE [7], and MOE [27]. These programs
stochastically rotate bonds at a pre-determined target
binding site and calculate the free energies of binding de
novo using derivations of the Schro¨dinger equation. As
solving the Schro¨dinger equation for a complex system
has an enormous number of variables for which to solve,
docking software was developed using density functional
theory and analogy to Newtonian molecular mechan-
ics. This method simplifies binding by looking at the
interaction as densities rather than electronic proba-
bility fields. Such simplifications led to three major
limitations in docking: 1) use of molecular mechanics
versus molecular dynamics, 2) implicit versus explicit
water, and 3) the expectation of a linear response ver-
sus real world sigmoidal response. However, recent de-
velopments in efficient software design and fast process-
ing hardware means it is now feasible to correct these
shortcomings. Disparate research groups are addressing
all of these problems using increasingly powerful accel-
erators such as graphics-processing units (GPUs) and
application-specific integrated circuits (ASICs).
The shortcoming of these softwares are their expecta-
tion of a normal statistical response, when in actuality
the response is inherently nonlinear and often stochas-
tic. This was done due to the large scaling in complexity
of using non-linear math. The complexity arises from
interactions featuring noncovalent protein-ligand inter-
actions which are a mixture of mostly hydrogen bonds,
ionic bonds, and hydrophobic bonds. Understanding
and simulation of hydrogen bonds and ionic bonds are
very good. However, hydrophobic bond calculations are
woefully underdeveloped. The real world energy con-
tributions of hydrophobic bonds is mostly derived by
the exclusion of water and altering the quantum net-
work of the adjacent hydration sphere. However, cur-
rent systems approximate this by taking two essentially
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Figure 1: Visual depiction of the PharML.Bind data inputs and neural network model, where GNN layers
are represented as 3D blocks, and traditional TensorFlow layers are represented as 2D blocks. ∗Distances in
the protein graph are 1.0/distance with a minimum value of 1.0/4A˚; edges with a smaller value are pruned.
in vacuo phase molecules, and approximating the par-
tial charges based on simplistic tables of the ionization
of amino acids at a given hydrated pH. This means all
the quantum effects and much of the induced effects are
not considered. The reason this is not done currently is
the difficulty in calculating entropy combined with the
added complexity of docking being a closed bimolecular
system.
However, artificial intelligence (AI) utilizing deep
graph neural networks (GNNs) presents an entirely dif-
ferent way to solve the problem [25]. Rather than us-
ing rules based on approximations of physics or clus-
tering similar molecules by organic chemistry / elec-
tronic properties, GNNs represent a form of process-
ing by which learning is performed without the intro-
duction of a large class of potentially-biased, human-
created rules. Instead of trying to derive the energy
of a complex de novo, ML can predict the probabil-
ity of a complex forming though neural network pat-
tern recognition. The approach has been implemented
on modest training scales in programs such as Quan-
tum.Ligand.Dock [13], AlgoGen [15], QPED [14], and
PotentialNet [26].
Protein-drug interactions are the basis for a drug’s
mechanism of action, referred to as pharmacodynamics
when speaking of the patient. While it is possible to get
direct experimental evidence of the specific interactions
though techniques like X-ray and NMR spectroscopy,
these techniques are arduous. Predicting protein-ligand
interactions is therefore of specific interest to scientists
in academia and the pharmaceutical industry who toil
in the drug discovery and development space. Predic-
tion of these interactions could help elucidate what the
mechanism of action is for a current drug, predict the
other proteins a ligand might bind to (i.e., off-target
interactions), and predict new classes of drugs for drug
development campaigns. In this regard, it can be ar-
gued the great need is not to create algorithms that best
match in vitro data quantitatively, but rather have the
ability to accurately predict the qualitative ability of
entities to interact in order to best prioritize quantita-
tive real-world experiments (i.e., quality of predictions
in some instances is more important than precision).
Most molecular interaction prediction software to
date comes in two basic types: 1) docking with in-
teraction energy equitation solving algorithms and 2)
chemical subgraph or e-state comparison such as near-
est neighbor and QSAR algorithms [8] [10]. However,
AI and ML approaches are gaining in number and inter-
est but come in a much wider array of basic premises.
The premise from the inception of PharML.Bind was
to do something substantially different from current
paradigms, and in particular, to leverage the power
of neural networks (NNs) to find answers, that from
an empirical and mathematical point of view, could be
very difficult to solve. For instance, trying to solve the
full Schro¨dinger equation for a dimer in a full biological
context is an overwhelming task. The primary reason
for this is that accurately stating the initial conditions
is imprecise and complicated further still by the local
minima problem, which is solved in docking by doing re-
peated measures. Switching the paradigm from trying
to accurately predict the true affinity, to being able to
discriminate and rank probable from improbable, pro-
vides a robustness that is much less sensitive to small
changes in initial conditions.
2 Motivation and Related Work
A major driver in drug discovery is the rate at which
new drugs can be characterized relative to a given tar-
get. It is helpful to define a metric to serve the purpose
of characterizing the number of simulations per second
one can utilize to rank protein-ligand pairings. This
work quantifies performance in terms of the number of
protein-ligand pairings which can be classified as either
Bind or No-Bind per second, that is protein-ligand pairs
per second (PLP/s).
A 2017 review of various approaches to docking found
significant variability in performance of predicted bind-
ing affinity accuracy across ten major docking applica-
tions [23]. Although some tools exist to discriminate
with good accuracy between different ligands based on
binding affinity for specific targets, they rely on sim-
ulation or random search to make predictions, making
them time-consuming to utilize in practice. These tools
usually provide a score of the ligand’s pose relative to
the target in 3D space or predict affinity directly based
on predicted hydrogen bonding patterns. In this case,
in silico accuracy is assessed in a non-data driven man-
ner through multiple measures with the premise that
correct answers will converge.
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Edgei (Bond) Nodei (Charge)
(Na, Nb,BondType) (Atomic, Formal)
E1 (1,2,4) E8 (8,4,4) N1 (6,0) N8 (6,0)
E2 (2,3,4) E9 (8,9,4) N2 (6,0) N9 (6,0)
E3 (3,4,4) E10 (9,1,4) N3 (6,0) N10 (6,0)
E4 (4,5,1) E11 (5,10,1) N4 (6,0) N11 (6,0)
E5 (5,6,2) E12 (10,11,1) N5 (6,0) N12 (7,0)
E6 (6,7,1) E13 (11,12,1) N6 (6,0)
E7 (7,8,1) N7 (7,0)
Figure 2: Two-dimensional chemical structure of tryptamine (left) along with the the corresponding undi-
rected ligand graph as a list of nodes and edges as input into the PharML.Bind neural network (right).
Both forms contain essentially the same information as the SMILES string “c1ccc2c(c1)c(c[nH]2)CCN”.
In contrast, training of NNs is data-driven, mean-
ing that NNs learn a mapping function (i.e., input to
output) from a distribution of examples, making them
highly sensitive to the quality and quantity of training
data. It is generally believed that these models make
use of hierarchies of learned features to make predic-
tions. However, unlike many other NNs, GNNs can
learn to detect such features in the input data in a way
which is more tolerant of many classes of input trans-
formations.
As an example, rotation, translation, and other or-
dering transformations applied to input data used with
contemporary convolutional neural networks (CNNs)
and other common architectures can cause important
features to be missed as learned features no longer line
up with the transformed input data. In order to learn
rotational invariance or other such symmetries, a CNN
can be trained with (potentially all) valid transforma-
tions applied to the input data, or can internalize some
of these transformations [17]. However, this data aug-
mentation approach can require training with up to N !
permutations of the data to make sure all possible ori-
entations are covered during training, where N is the
number of input values fed to dense and similar layers
in the neural network [16]. This frequently represents
an intractable amount of additional training time for
large molecules and even small proteins. In contrast,
GNNs are able to process input data in a way which
is invariant to rotation, translation, and other ordering
transformations. This effectively allows GNNs to learn
tasks with fewer training examples. Specifically, GNNs
can learn the representation of a molecule and its re-
lationship to a given protein target from only a single
disjoint graph containing the two entities. This could
otherwise require N ! permutations of the input data in
order to be learned by a CNN or fully-connected net-
work.
3 Methods and Key Results
This work’s recommended approach uses an ensemble
of GNNs which takes as input graph representations
of protein-ligand pairings, and then outputs a binary
classification, either Bind or No-Bind. Dataset process-
ing, model implementation specifics, and key results are
provided in this section.
3.1 Dataset Preparation and Analysis
In molecular docking, using a data-driven approach
(e.g., data coming from X-Ray, Cryo-EM, or NMR ex-
periments) enables a model to utilize the physical prop-
erties of binding states which occur in experimental
data. The physical properties which the model can
learn and use to make predictions are mainly limited by
the resolution and experimental quality. Using graphs
for both the protein and ligand in a sparse format con-
sisting of a list of edges and a list of nodes allows for
more efficient use of processing and memory during
training than is possible with rasterized and other such
dense approaches.
A single input which is fed to the GNN is given
as a protein-ligand pair. To give a specific example
of the ligand graph input format, consider the input
graph for tryptamine, presented in Figure 2, with hy-
drogen excluded for clarity. Note that both representa-
tions in the figure contain the same information as the
SMILES string “c1ccc2c(c1)c(c[nH]2)CCN”. On the
protein side, the conversion from a PDB to a protein
neighborhood graph (NHG) is similar, but uses different
node and edge attributes. Specifically, the protein NHG
is the same as the ligand graph, except that the bond
type is replaced with 1/distance in Angstroms (with a
minimum value of 1/4A˚, else the edge is removed) and
only the atomic charge is used with the formal charge
excluded.
BindingDB (BDB) is processed from a single SDF
data file, BindingDB-All-terse-2D-2019m7.sdf, to extract
information on proteins, ligands, and their interactions
[4][6][3]. Proteins in BindingDB are specified by Pro-
tein Data Bank (PDB) [2] IDs, ligands are specified
by SMILES strings, and their associated affinities are
in the form of IC50 values. These entries from Bind-
ingDB and PDB are then examined for issues, such
as an invalid SMILES string (as interpreted by RD-
Kit [31]) or a protein with too many (>10, 000) or too
few (< 500) atoms, discarding items failing validation.
The resulting protein-ligand pairs are then classified as
either Bind (IC50 ≤ 10,000 nM) or NoBind (>10,000
nM). Finally, the PDB and SMILES data are converted
to their respective graph formats.
Data produced by the cleaning and format conversion
process is then balanced to contain an equal number
of Bind and NoBind examples, after which it is split
into training, validation, and test sets as listed in Table
1. This data splitting is performed on the protein axis,
such that a given PDB ID occurs in exactly one dataset.
Notice that the largest training set used is only 25%
of the total available data from BindingDB after pre-
processing. The remaining 75% of the dataset is used
to test model generalization.
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(a) Bind and No-Bind (b) Bind
Figure 3: Heat map pair-wise similarity matrices, indicating global diversity and local similarity of drugs.
(a) Similarity of Bind and No-Bind ligands from the validation dataset (see Table 1) across a variety of
specific protein classes, as well as (b) similarity of data classified Bind from (a). Heat maps are generated
using Chemmine [12]. Green is highly similar and red is highly dissimilar.
Dataset BDB Pairs Proteins Ligands
ensemblea 5% 167,656 1,293 85,591
ensembleb 5% 155,567 1,283 82,646
ensemblec 5% 163,288 1,294 85,441
ensembled 5% 161,341 1,291 90,238
ensemblee 5% 174,342 1,291 87,604
mono10 10% 323,223 2,576 121,871
mono15 15% 486,511 3,870 147,632
mono20 20% 647,852 5,161 167,086
mono25 25% 842,693 6,496 183,126
validation 1% 26,051 259 22,286
testing 75% 2,708,151 19,709 247,633
Table 1: Details for ensemble and monolithic train-
ing datasets, as well as datasets used for validation
to detect convergence. Details on the test set used
for final evaluation are also provided.
The threshold IC50 score which was used to cate-
gorize pairings as Bind or No-Bind can be analyzed
for fairness through similarity clustering analysis, as
shown in Figure 3a along with the similarity among
pairs within only the Bind category is shown in Fig-
ure 3b. These data indicate splitting the data would
have equivalent effects on training for both Bind and
No-Bind, leading to more robust prediction for either
actives or inactives. Very uneven splits would bias the
predictions to have accuracy for either Bind or No-
Bind.
3.2 Model Architecture and Training
The choice of model architecture has important ramifi-
cations for allowable mappings (i.e., inputs to outputs),
achievable accuracy, and generalization capabilities.
Thus, the GNN architecture created for PharML.Bind
is designed to have an active-site-agnostic mapping and
architectural details which optimize training and infer-
ence with graph-based chemical data. The model is
implemented in Python using TensorFlow [18].
CNN architectures commonly used with image data,
such as architectures similar to those used by LeNet [1]
and ResNet [20], do not directly propagate information
from earlier layers all the way to the later dense layer(s).
Initial features extracted by the first convolutional lay-
ers are simple gradients and basic curves, while what
is most important for input to the final classification
layers are the higher-level, more-complex features ex-
tracted by the last convolutional layer. However, com-
pared to traditional CNNs on image data, even low-
level features involving only a few atoms can be very
important in the chemical space. For this reason, the
PharML.Bind NN architecture carries all output fea-
tures forward as each message-passing layer is added,
as can be seen in Figure 1 and Table 2. Also, note that
the sizes of the MLP NNs used for φ in the cores increase
with depth, as later layers have more input features to
consider than earlier layers.
Weights for each message-passing step (i.e., Corei)
are independent and not shared with other cores. This
design choice is motivated by the idea that each Corei
transforms one input latent representation Li into an-
other output latent representation Lj , and it is undesir-
able to “overload” the NNs which make up each core.
That is, each core / message-passing step should have
its own Li → Lj mapping, as opposed to other com-
mon approaches that give each edge type independent
weights but share weights across steps [21].
GNN Layer Layer Sizes for MLP φ
Encode 32, 32
Core0 32, 7
Core1 40, 9
Core2 48, 29, 48
Core3 56, 41, 27, 56
Core4 64, 51, 39, 51, 64
Decode 32, 32
Output 64
TF Layer Size
Dense0 128 with dropout 0.5
Dense1 128
Output 2
Table 2: Layer sizes used, where φ is a multilayer
perceptron (MLP) for each of φe, φv, and φu in
PharML.Bind’s Corei layers as well as the Encode
and Decode GNN layers [25]. The output GNN layer
only uses φu.
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A cyclical learning rate (CLR) was used during train-
ing with a triangular waveform which completed one cy-
cle every 5 epochs [8]. This use of CLR was combined
with a learning rate decay schedule by setting the base
learning rate used by the CLR during training to the
decay function. An initial learning rate of `0=1×10−8
was used, and scaled by Nworkers as additional workers
were added to speed up the training time. Convergence
was defined as 15 training epochs without improvement
in validation accuracy. A 1% subset of the 75% test set
was used to test for convergence. This was found to be
a decent proxy for performance on the full 75% test,
and allowed for a validation phase to be run after each
epoch to check for convergence without impacting the
overall training time significantly.
3.3 Experimental Results
Results from performed experiments demonstrate that
test accuracy and generalization improve as more train-
ing data are used. For the largest dataset, 25% of the
available pairings in BindingDB were used for training,
with 75% for testing. This is an inversion of the size
ratio utilized for traditional training and test datasets,
but quite useful to illustrate that the Bind / No-Bind
prediction task has truly been learned by the model
in a way that generalizes across many more pairings
than ever observed during training. This result implies
the model has learned actionable physical rules from
the data given. Overall, the best model was able to
achieve 98.3% accuracy on the largest test set, contain-
ing 2,708,151 pairs from BindingDB in under 25 min-
utes. This represents use of 100% of the full, filtered
BindingDB dataset, the model being trained on only
25% of it, with the remainder reserved for validation
and testing.
Figure 4: Enrichment factors [5] and accuracy for
PharML.Bind testing with different ensemble sizes
on BindingDB.
Table 3 provides results which show that an ensem-
ble of multiple GNNs provides a higher accuracy than
training a single monolithic GNN with the same amount
of data. These results from testing with BindingDB
alone may not adequately motivate the use of ensem-
bles due to the requisite increase in model complexity as
well as the associated increase in training and inference
time. However, results from testing performed with the
ZINC15 dataset [19] against an instance of the 5-HT re-
ceptor (i.e., PDB ID “5TVN”) as presented in Figure 5
do provide solid motivation for the use of ensembles. As
shown in the figure, monolithic GNNs trained with in-
creasing dataset sizes result in an increase in predicted
binds from ZINC15, with the largest training set pro-
ducing a bind prediction for more than 25% of the lig-
ands (a similar increasing trend is seen with BindingDB
in Table 3). This bind prediction rate is too high to
be considered accurate. In contrast, the ensemble ap-
proach predicts binds using ZINC15 at a much more
realistic and useful rate of approximately 1.2%, while
at the same time performing better on BindingDB.
Train Accuracy (%) Bind Predictions (%)
(BDB%) (Ensemble/Monolithic)
5 88.9 / 88.9 48.1 / 48.1
10 95.2 / 93.2 40.7 / 48.3
15 97.0 / 95.1 37.1 / 48.8
20 97.9 / 96.2 34.6 / 49.2
25 98.3 / 96.8 33.2 / 49.7
Table 3: Accuracy of monolithic training runs com-
pared to ensembles (each ensemble member trains on
5% of BindingDB).
Figure 5: Percent of the Zinc15 dataset predicted
to bind to the target protein for varying numbers of
ensemble members as well as monolithic NNs.
The effectiveness of the ensemble approach might be
explained by the dissimilarity between the ligands found
in BindingDB and ZINC15. A GNN will be more likely
to make an essentially random prediction for a ligand
unlike those it has been trained with as compared to
those ligands it has seen during training. Thus, an en-
semble of GNNs will be able to probabilistically reject
these “uncertain” predictions at a higher rate than the
monolithic approach.
3.4 Performance
As described in Section 3.3, GNNs were used to in-
ference the test set after training converged. The test
set was run on a cluster consisting of Cray CS-Storm
servers with 4 V100 GPUs attached to each socket of
Intel E52697-v4 36-core host processors. PharML.Bind
achieved a record-breaking rate of 195 protein-ligand
5
pairs per second (PLP/s) on one state-of-the-art Nvidia
V100 GPU. When using 16 servers with 64 V100s, per-
formance scales to over 3000 PLP/s. Speed improve-
ment is given by:
Rplp = αKgpu
Nplp
∆t
, (1)
where Rplp is the rate of protein-ligand pairs inferenced
per second (PLP/s), α is a scaling factor, Kgpu is the
number of GPU resources utilized, Nplp is the number
of protein-ligand pairs inferenced over the time interval
∆t, and ∆t is the time spent inferencing Nplp examples.
As a proxy for and instance of traditional simulation
methods, MOE Dock was used to predict affinity for
83 compounds across the whole surface of a CA4 tar-
get protein. The simulation was run for 105 hours
on a 4-core Xeon W3565 3.2GHz processor. Over the
course of the simulation, all 8 threads of the CPU were
utilized 75% of the time. We use this performance as
a baseline model of MOE Dock to estimate how the
application would theoretically perform when run on
the same host CPU hardware comprising the servers on
which PharML.Bind was run.
MOE Dock achieves 2.19×10−4 PLP/s on a Xeon
W3565. Adjusting for differences between the sys-
tems, MOE Dock is projected to achieve 136.2×10−4
PLP/s on an extrapolated system to that used with
PharML.Bind. Using the performance model of MOE
described above, PharML.Bind offers a speedup factor
of over 14,000x improvement over MOE Dock in terms
of raw time to arrive at actionable predictions about
protein-ligand pairings. We can bound the improve-
ment factor by setting the MOE performance model
to be either 100% compute-bound, or 100% memory
bandwidth bound, which assumes that MOE Dock per-
formance is boosted entirely by either the improve-
ments in memory bandwidth or compute capability
of the E52697-v4 36-core server relative to the Xeon
W3565 based server. These bounds result in a mini-
mum speedup of 11,000× and a maximum speedup of
37,000×, as shown in Table 4.
System Model PLP/s
PharML.Bind on 4 GPUs 195
MOE on 8 CPUs 136.2×10−4
Upper Bound (Mem. BW Limited) 52.6×10−4
Lower Bound (Compute Limited) 164.1×10−4
System Model PharML.Bind
Speedup
MOE on 8 CPUs 14,363×
Upper Bound (Mem. BW Limited) 37,215×
Lower Bound (Compute Limited) 11,922×
Table 4: Performance comparison showing
PharML.Bind speedup factor over MOE Dock
along with upper and lower bounds implied by the
performance model.
4 Summary
By utilizing state-of-the-art deep graph networks,
PharML.Bind provides modular building blocks to en-
able high-throughput drug discovery. This data-driven
approach enables early affinity-based decisions on drug
viability for specific whole-protein targets. The efficient
performance of the distributed training and inference
algorithms can scale linearly with compute resources if
provided sufficient volumes of data. This work demon-
strates that increasing the amount of training data fed
to a particular network improves its generalization ca-
pabilities. By breaking the training data into non-
overlapping chunks, ensembles of smaller models can
be trained. This work demonstrates that the aggregate
performance of an ensemble against a single monolithic
model trained on the same fraction of the data can
significantly improve generalization and simultaneously
provide mechanisms for drug scoring. Trained GNN
models have the potential to replace traditional protein-
drug docking approaches (e.g., simulation) if such ML
approaches can generalize sufficiently well to previously
unseen drug-target pairings.
In the frequent case that a desired end goal is to
determine if a drug is a viable candidate for further in-
vestigation relative to a whole protein, PharML.Bind
demonstrates the ability to predict affinity across 75%
of the protein-ligand pairings present in BindingDB
with over 93% accuracy using a single GNN. Further-
more, this work shows that the accuracy of the model
can be improved by increasing the amount of training
data sufficiently (see Table 3), making it interesting as
a potential means of making efficient use of the ever-
expanding databases of X-Ray, NMR, and CryoEM ex-
periments. When more data are used in training, that
accuracy can jump to over 96% in testing on 75% of
BindingDB with a single model. Utilizing ensembles
of GNNs trained on subsets from the same 25% of
BindingDB, the accuracy on the 75% test set exceeded
98% and allowed the rank-ordering of the tested com-
pounds. These accuracies are expected to improve with
hyperparameter optimization (HPO), as the layer sizes
and training regime used in this work represent a very
small, manual search of the available hyperparameter
space. Future work includes plans to use population-
based training (PBT) [30][22].
In addition, PharML.Bind makes use of scalable
data-parallel training algorithms, meaning the time it
takes to train a new model on even the largest databases
can be scaled down linearly with increasing computa-
tional resources. This same technique lends itself to
support large-scale parallel inference. The model uses
a graph-based approach, which aside being far more
efficient than volumetric approaches also enables effi-
cient learing of mappings from common features con-
tained within PDB and SDF data structures to action-
able results. By utilizing graph neural networks and
large HPC systems, drug discovery can be scaled to un-
precedented levels in terms of both prediction accuracy
and throughput.
4.1 Conclusions
The potential impact from tools which predict affin-
ity for arbitrary target proteins in a scalable man-
ner opens up the possibility of finding candidate drugs
across the entire corpus of experimental data gath-
ered through CryoEM, NMR, and X-Ray crystalogra-
phy data available to date. This expanding frontier
of available data enables solutions to previously in-
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tractable problems. Our results demonstrate that en-
sembles of PharML.Bind GNN models can be trained
on small, independent subsets of BindingDB (or simi-
lar PDB / SDF based datasets) to provide rank-ordered
candidate drug listings across tens-of-thousands of pro-
teins and millions of drugs in an active-site-agnostic
manner. The resolution of the ranking can be improved
simply by training more models.
Furthermore, the number of nodes and edges that de-
fine the graphs used to represent the ligand and protein
pairing is limited only by memory capacity, meaning
that mappings against large-molecule or protein-protein
pairings are likely amenable to similar speedup factors
as those shown in this work. This is especially criti-
cal for unannotated proteins which currently represent
about a fifth of the human transciptome [24].
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